CA Patent

CA2100569A1 — Compositions

Assigned to Glaxo Group Ltd · Expires 1992-07-25 · 34y expired

What this patent protects

A pharmaceutical composition in a form adapted for intranasal administration which comprises a suspension of 3-2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide or a suitable physiologically acceptable salt or solvate thereof as active ingredient, wherein the pH is…

USPTO Abstract

A pharmaceutical composition in a form adapted for intranasal administration which comprises a suspension of 3-2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide or a suitable physiologically acceptable salt or solvate thereof as active ingredient, wherein the pH is in the range of 8 to 12. The intranasal compositions are of use in the treatment of conditions associated with cephalic pain, in particular migraine.

Drugs covered by this patent

Patent Metadata

Patent number
CA2100569A1
Jurisdiction
CA
Classification
—
Expires
1992-07-25
Drug substance claim
No
Drug product claim
No
Assignee
Glaxo Group Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.